Charles Schwab Investment Management Inc. Purchases 2,954 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Charles Schwab Investment Management Inc. grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 1.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 243,170 shares of the company's stock after purchasing an additional 2,954 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.85% of Krystal Biotech worth $38,095,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. US Bancorp DE raised its holdings in Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the last quarter. Illinois Municipal Retirement Fund raised its stake in shares of Krystal Biotech by 11.9% during the fourth quarter. Illinois Municipal Retirement Fund now owns 14,146 shares of the company's stock valued at $2,216,000 after acquiring an additional 1,505 shares during the last quarter. Hussman Strategic Advisors Inc. purchased a new stake in shares of Krystal Biotech during the fourth quarter worth about $658,000. TimesSquare Capital Management LLC grew its stake in shares of Krystal Biotech by 39.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company's stock worth $24,888,000 after purchasing an additional 44,646 shares during the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in Krystal Biotech during the 4th quarter valued at about $231,000. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Price Performance

NASDAQ KRYS traded up $0.98 during trading hours on Wednesday, reaching $189.48. 87,955 shares of the company's stock traded hands, compared to its average volume of 283,780. The firm has a market cap of $5.46 billion, a PE ratio of 63.26 and a beta of 0.87. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34. The firm has a 50-day simple moving average of $164.69 and a 200 day simple moving average of $173.58.

Remove Ads

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. During the same period in the previous year, the firm posted $0.30 EPS. The business's revenue for the quarter was up 116.4% compared to the same quarter last year. Sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

Wall Street Analyst Weigh In

KRYS has been the subject of several research analyst reports. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Chardan Capital lifted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. HC Wainwright reissued a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of "Buy" and an average target price of $220.00.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).